Macrogen Selects N-of-One
News Apr 08, 2016
N-of-One, Inc. has announced that Macrogen Corp. has selected N-of-One to provide high-quality clinical interpretation for its newly launched clinical next-generation sequencing (NGS) panels used for cancer patients. Financial terms of the agreement are not disclosed. The genomic tests showcase highly advanced DNA screenings that identify specific genes and genetic mutations in a patient’s genome that are related to major cancers and genetic diseases.
The use of Next Generation Sequencing technology makes it possible to process, sequence, and analyze large volumes of genes and long strands of genetic code, thereby allowing individualized treatment plans to be accessible. N-of-One’s patient-specific analysis identifies therapeutic options based on each patient’s specific molecular profile identified by the sequencing data.
These therapeutic options include therapies in guidelines, off label therapies, and the most relevant clinical trials prioritized based on molecular and geographical relevance. “The partnership between Macrogen and N-of-One will further strengthen Macrogen’s growth in the clinical setting to enable accessibility of personalized medicine,” said Sang Tae Park, Ph.D., the CEO of Macrogen Corp.
“It will deliver comprehensive and clear reports including therapeutic options suited to each patient with information of molecular/clinical relevance and eligible clinical trials for the rapidly growing number of clinical cancer NGS test results.” “N-of-One is very pleased to partner with Macrogen, supporting their goal of delivering the highest quality report at a cost effective price”, said Chris Cournoyer, CEO at N-of-One.
Southeast Asian Nomads Have Evolved to Hunt Fish UnderwaterNews
The human spleen can release oxygenated blood cells to allow more time underwater without breathing. A new study has identified that the "Sea Nomad" Bajau people of Indonesia have evolved larger spleens that would allow them to remain underwater for longer.READ MORE
Gene Therapy Could End Transfusions for Blood Disorder PatientsNews
Beta-thalassemia patients need a regular dose of red blood cells transfused into their body. A new gene therapy that edits faulty genes in the patients' cells could end this monthly ritual.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
29th International Conference on Public Mental Health and Neuroscience
Jul 16 - Jul 18, 2018
International Conference on Epigenetics and Epitranscriptomics
Sep 17 - Sep 18, 2018